Literature DB >> 23049300

Clinical applications of immunoglobulin: update.

Marcia Cristina Zago Novaretti1, Carla Luana Dinardo.   

Abstract

Human immunoglobulin is the most used blood product in the clinical practice. Immunoglobulin applications have increased quickly since the elucidation of its immunomodulatory and antiinflammatory properties which turned this blood product into a precious tool in the treatment of numerous diseases that present with humoral immune deficiency or that cause immune system dysfunction. Currently, the approved indications for Ig are: primary immunodeficiencies, secondary immunodeficiencies (multiple myeloma or chronic lymphoid leukemia), Kawasaki syndrome, immune thrombocytopenic purpura, Guillain Barré syndrome, graft-versus-host disease following bone marrow transplantation and repeat infections in HIV children. On the other hand, there are numerous "off-label" indications of immunoglobulin, which represent 20-60% of all clinical applications of this drug. It is important to study all these indications and, above all, the scientific evidence for its use, in order to provide patients with a new therapeutic option without burdening the health system. This review results from a wide selection of papers identified in the Pubmed and Lilacs scientific electronic databases. A group of descriptors were used from human immunoglobulin to the names of each disease that immunoglobulin is clinically applied. Our main objective is to list the numerous indications of immunoglobulin, both authorized and "off-label" and to analyze these indications in the light of the most recent scientific evidence.

Entities:  

Keywords:  Guillain-Barre syndrome; Immune system diseases; Immunoglobulin, intravenous; Plasma; Purpura, thrombocytopenic, idiopathic

Year:  2011        PMID: 23049300      PMCID: PMC3415732          DOI: 10.5581/1516-8484.20110058

Source DB:  PubMed          Journal:  Rev Bras Hematol Hemoter        ISSN: 1516-8484


  92 in total

Review 1.  Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn.

Authors:  R Gottstein; R W I Cooke
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

2.  A second case of post-transfusion purpura caused by HPA-5a antibodies: successful treatment with intravenous immunoglobulin.

Authors:  A Ziman; E Klapper; S Pepkowitz; R Smith; G Garratty; D Goldfinger
Journal:  Vox Sang       Date:  2002-08       Impact factor: 2.144

3.  Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.

Authors:  Naveed Sami; Ansa Qureshi; Eleonora Ruocco; A Razzaque Ahmed
Journal:  Arch Dermatol       Date:  2002-09

4.  Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis.

Authors:  M Meissner; Y Sherer; Y Levy; H Chwalinska-Sadowska; P Langevitz; Y Shoenfeld
Journal:  Rheumatol Int       Date:  2000       Impact factor: 2.631

5.  Intravenous immunoglobulin G in the treatment of patients with chronic glomerulonephritis: clinical experience lasting 15 years.

Authors:  Daniela Monova; Nicolay Belovezhdov; Iskra Altunkova; Simeon Monov
Journal:  Nephron       Date:  2002-03       Impact factor: 2.847

6.  Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression.

Authors:  Nicolas Bachot; Jean Revuz; Jean-Claude Roujeau
Journal:  Arch Dermatol       Date:  2003-01

7.  Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases.

Authors:  Christa Prins; Francisco A Kerdel; R Steven Padilla; Thomas Hunziker; Sergio Chimenti; Isabelle Viard; Davide N Mauri; Kirsten Flynn; Jennifer Trent; David J Margolis; Jean-Hilaire Saurat; Lars E French
Journal:  Arch Dermatol       Date:  2003-01

8.  Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience.

Authors:  Jennifer T Trent; Robert S Kirsner; Paolo Romanelli; Francisco A Kerdel
Journal:  Arch Dermatol       Date:  2003-01

Review 9.  Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates.

Authors:  G S Alcock; H Liley
Journal:  Cochrane Database Syst Rev       Date:  2002

10.  Use of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome.

Authors:  B Lee Peterlin; William Flood; Milind J Kothari
Journal:  J Am Osteopath Assoc       Date:  2002-12
View more
  2 in total

Review 1.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

2.  Hemolysis induced cross-matching difficulty with intravenous immunoglobulin: a case report.

Authors:  Achyut Sharma; Diptesh Aryal
Journal:  J Med Case Rep       Date:  2018-09-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.